Phase III Study of a Therapeutic Vaccine Candidate Containing Hepatitis B Virus (HBV) Core Antigen (HBcAg) and HBV Surface Antigen (HBsAg) for Treatment of Patients With Chronic HBV Infection.
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2013
At a glance
- Drugs ABX 203 (Primary) ; Peginterferon alfa-2b
- Indications Hepatitis B
- Focus Therapeutic Use
- 28 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 26 Apr 2013 Status changed from active, no longer recruiting to completed.
- 26 Apr 2013 Primary endpoint 'Virological-response-rate' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History